Abstract

Parameter estimation in mathematical models that are based on differential equations is known to be of fundamental importance. For sophisticated models such as age-structured models that simulate biological agents, parameter estimation that addresses all cases of data points available presents a formidable challenge and efficiency considerations need to be employed in order for the method to become practical. In the case of age-structured models of viral hepatitis dynamics under antiviral treatment that deal with partial differential equations, a fully numerical parameter estimation method was developed that does not require an analytical approximation of the solution to the multiscale model equations, avoiding the necessity to derive the long-term approximation for each model. However, the method is considerably slow because of precision problems in estimating derivatives with respect to the parameters near their boundary values, making it almost impractical for general use. In order to overcome this limitation, two steps have been taken that significantly reduce the running time by orders of magnitude and thereby lead to a practical method. First, constrained optimization is used, letting the user add constraints relating to the boundary values of each parameter before the method is executed. Second, optimization is performed by derivative-free methods, eliminating the need to evaluate expensive numerical derivative approximations. The newly efficient methods that were developed as a result of the above approach are described for hepatitis C virus kinetic models during antiviral therapy. Illustrations are provided using a user-friendly simulator that incorporates the efficient methods for both the ordinary and partial differential equation models.

Highlights

  • Chronic viral hepatitis is a major public health concern.Approximately 500 million individuals worldwide are living with chronic viral hepatitis; above a million of those who are infected die each year, primarily from cirrhosis or liver cancer resulting fromMathematics 2020, 8, 1483; doi:10.3390/math8091483 www.mdpi.com/journal/mathematicsMathematics 2020, 8, 1483 their hepatitis infection [1,2,3]

  • Deaths related to chronic hepatitis are as many as those due to human immunodeficiency virus (HIV) infection, tuberculosis, or malaria [4], and are projected to exceed the combined mortality associated with HIV infection, tuberculosis, and malaria by 2040 [5]

  • Because of precision problems in [57] encountered with Levenberg–Marquardt that caused the parameter estimation procedure to become highly non-efficient, we developed an efficient constrained optimization procedure that is based on damped Gauss–Newton instead such that we avoid problematic use of derivatives, while alternatively offering the possibility to apply Powell’s Constrained optimization by linear approximation (COBYLA) [61] for the optimization procedure

Read more

Summary

Introduction

Chronic viral hepatitis (hepatitis C, hepatitis B, and hepatitis D) is a major public health concern.Approximately 500 million individuals worldwide are living with chronic viral hepatitis; above a million of those who are infected die each year, primarily from cirrhosis or liver cancer resulting fromMathematics 2020, 8, 1483; doi:10.3390/math8091483 www.mdpi.com/journal/mathematicsMathematics 2020, 8, 1483 their hepatitis infection [1,2,3]. Chronic viral hepatitis (hepatitis C, hepatitis B, and hepatitis D) is a major public health concern. 500 million individuals worldwide are living with chronic viral hepatitis; above a million of those who are infected die each year, primarily from cirrhosis or liver cancer resulting from. Mathematics 2020, 8, 1483 their hepatitis infection [1,2,3]. A deeper understanding of hepatitis B and D infection dynamics is needed to enable the development of more curative therapeutics. Despite the significant advances in hepatitis C therapy, it is widely acknowledged that cost remains a major barrier for achieving global elimination. There still exists a need for affordable therapy with similar high efficacy and with much shorter treatment durations and vaccine development

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call